More News

11 July 2018

Otsuka Pharmaceutical to Acquire Visterra

11 July 2018

Idera Pharmaceuticals Announces Termination of Merger Agreement with BioCryst Pharmaceuticals

10 July 2018

BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases

10 July 2018

Adlai Nortye Announce Global License Agreement for Buparlisib (BKM120)

10 July 2018

NIH and Matinas BioPharma Announce Research Collaboration to Identify Novel HIV Therapy Utilizing LNC Platform Delivery Technology

10 July 2018

MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers

10 July 2018

Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma

3 July 2018

TRIGR Therapeutics and ABL Bio Announce Global Oncology Collaboration on Pipeline of Next Generation Therapeutic Antibodies

2 July 2018

Athenex Announces Pipeline Expansion Initiatives in Conjunction with a Strategic Investment of $100 million by Perceptive Advisors

1 July 2018

Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop Proprietary Fusion Proteins for the Treatment of NASH and Metabolic Diseases

29 June 2018

APEIRON, the Medical University of Vienna and the Institute of Molecular Biotechnology Sign Licensing Agreement for a New Checkpoint Inhibitor

29 June 2018

Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn

29 June 2018

Biogen Exercises Option to Increase Ownership in Samsung Bioepis

28 June 2018

Devonian Announces the Signing of a Non-Binding Letter of Intent with Folia Biotech to develop FB-631 in cancer immunotherapy

28 June 2018

MolMed and AbCheck sign a three-year Master Agreement for the development of new CARs targeting novel tumor antigens

28 June 2018

Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease

28 June 2018

NBE Therapeutics Closes a CHF 20 Million Financing by Novo Holdings A/S

28 June 2018

Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar

27 June 2018

GC LabCell and Feldan Therapeutics announce license agreement to develop next-generation NK cells for immunotherapy using Feldan Shuttle technology

27 June 2018

AbbVie and Calico Announce Extension of Groundbreaking Collaboration

27 June 2018

Skyhawk Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing Modifiers using Skyhawk’s STAR* Technology Platform

26 June 2018

Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease

26 June 2018

Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases

25 June 2018

AbbVie and Calibr announce collaboration for next generation T-cell therapies

20 June 2018

TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody

19 June 2018

Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes

19 June 2018

NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma’s new subsidiary Fortify Therapeutics

14 June 2018

Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program

11 June 2018

BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Origin Biosciences to Develop and Commercialize Therapy

11 June 2018

Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology From National University of Singapore and St. Jude Children’s Research Hospital

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Ranibizumab (Lucentis) Biosimilars Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis